Skip to main content

Table 3 The CAMARADES quality items

From: The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimer’s disease: a systematic review

Study

Quality score

Wang YC et al. 2014

 

 

 

7

Bombi Lee et al. 2013

 

 

8

Song XY et al. 2013

   

 

6

Quan QK et al. 2013

    

6

Zhao HH et al. 2012

    

6

Wang YL et al. 2010

  

  

?

 

4

Zhang X et al. 2012

 

 

8

Chu SH et al. 2014

 

   

?

 

4

Zhou LP et al. 2011

     

 

4

Wang XY et al. 2001

   

 

6

Wu W et al. 2011

     

 

4

Zang Y et al. 2010

    

 

5

  1. (1) peer reviewed publication; (2) presence of randomization of subjects into treatment groups; (3) assessment of dose–response relationship; (4) blinded assessment of behavioural outcome; (5) monitoring of physiological parameters such as body temperature; (6) calculation of necessary sample size to achieve sufficient power; (7) statement of compliance with animal welfare regulations; (8) avoidance of anaesthetic agents with marked intrinsic neuroprotective properties (e.g., ketamine); (9) statement of potential conflict of interests; (10) use of a suitable animal model